PROCEPT BioRobotics' Aquablation therapy has been upgraded to a strong recommendation in the updated European Association of Urology Guidelines as a preferred surgical treatment for benign prostatic ...

World’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for ...

Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...

The purpose of this manuscript is to provideclinicians, health plan decision makers, and policymakers with highlights of key findings pertainingto our current understanding of the condition ofenlarged ...

Entadfi is a fixed-dose combination of finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. The Food and Drug Administration (FDA) has approved Entadfi ...

Extracts of the berries of saw palmetto, a small palm tree native to the southeastern U.S., are used widely to treat benign prostatic hyperplasia (BPH). In this randomized trial conducted in ...

Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasiaSAN JOSE, Calif., March 23, ...

Drug Used for Enlarged Prostate Tied to High Glaucoma Risk The use of alpha-blockers for benign prostatic hyperplasia is tied to an increased risk of developing acute angle-closure glaucoma, a study ...

Benign prostatic hyperplasia (BPH) is a prevalent condition characterised by the non-malignant enlargement of the prostate gland, which frequently precipitates lower urinary tract symptoms (LUTS).

Widely used medications for benign prostatic hyperplasia (BPH) - also known as enlarged prostate - may be associated with a small, but significant increase in the probability of developing heart ...